A Phase 1, Single Centre, Single-blind, Randomized, Placebo-controlled Parallel-group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Administration of Single Ascending Doses in Healthy Male Japanese Subjects
Latest Information Update: 04 Jan 2021
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors AstraZeneca
- 28 Dec 2020 Data from 7 studies (NCT00757042, NCT00972179, NCT01405963, NCT01913028, NCT02512900, NCT02525094 & NCT02054130) was used to develop a population PK model to guide tezepelumab dose selection for phase III trials in patients with severe asthma, published in the Journal of Clinical Pharmacology.
- 20 Jan 2020 Results assessing the safety, tolerability, PK, and immunogenicity of tezepelumab in healthy Japanese male volunteers published in the Clinical Pharmacology in Drug Development
- 11 Feb 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.